Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics (DE:2LB)
:2LB
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.4Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -0.08%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call demonstrated strong revenue performance and positive market adoption for Amtagvi, with significant highlights in manufacturing capacity and pipeline progress. However, high operating costs and the need for acceleration in adoption at ATCs present challenges.Company Guidance
In the Iovance Biotherapeutics fourth quarter and full year 2024 financial results conference call, the company reported a total product revenue of $73.7 million for Q4 and $164.1 million for the full year, meeting the upper end of their guidance range of $160 million to $165 million. The revenue comprised $48.7 million from Amtagvi and $25.0 million from Proleukin in Q4, with full year figures at $103.6 million and $60.5 million, respectively. Iovance treated over 200 patients with Amtagvi in its partial first year of launch. The guidance for 2025 is set at $450 million to $475 million in total product revenue, driven by anticipated growth in both Amtagvi and Proleukin sales. The company has a staffed capacity to supply over 1,200 patients annually and aims to expand its network of authorized treatment centers (ATCs) to meet increasing demand. The gross margin for Q4 improved significantly and is on track to surpass 70% in the coming years, while cash burn is expected to decrease, further supporting the company's path toward profitability.Strong Revenue Performance
Total product revenue reached $73.7 million in Q4 and $164.1 million for the full year 2024, achieving the upper end of guidance. Amtagvi generated $103.6 million, and Proleukin earned $60.5 million for the year.
Positive Market Adoption
Over 200 patients treated with Amtagvi in its first year. 70 authorized treatment centers (ATCs) are active, covering 32 states, with over 95% of U.S. lives having reimbursement access.
Manufacturing Capacity and Expansion
Current manufacturing capacity can support over 1,200 patients annually, with plans to expand to over 5,000 patients in the future.
Pipeline and Regulatory Progress
U.S. and global expansion plans for Amtagvi are on track, with potential approvals in the UK, Canada, and the EU in 2025. Ongoing trials for advanced melanoma and non-small cell lung cancer show promise.
---
DE:2LB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:2LB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | €5.13 | €5.13 | 0.00% |
| Nov 07, 2024 | €11.52 | €9.10 | -20.97% |
| Aug 08, 2024 | €6.69 | €9.10 | +36.02% |
| May 09, 2024 | €12.35 | €10.38 | -15.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Iovance Biotherapeutics (DE:2LB) report earnings?
Iovance Biotherapeutics (DE:2LB) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Iovance Biotherapeutics (DE:2LB) earnings time?
Iovance Biotherapeutics (DE:2LB) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Iovance Biotherapeutics stock?
The P/E ratio of Iovance Biotherapeutics is N/A.
What is DE:2LB EPS forecast?
DE:2LB EPS forecast for the fiscal quarter 2025 (Q1) is -0.23.
---